title: [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
abstract: OBJECTIVE
  To evaluate the prognostic value of HER2 expression in non-muscle invasive bladder transitional cell carcinoma (TCC) with special emphasis in the high grade population. MATERIALS AND METHODS (PATIENTS): Tissue microarrays (TMA) were performed with representative TUR-B specimens from 84 patients with non-muscle invasive bladder TCC (40 pT1GII and 44 pT1GIII) treated in our institution. Depth of invasion and grade were uniformly assigned by the same pathologist who performed blind immunohistochemical analysis with Hercep test: 3+ was considered strong positive HER2 overexpression. Other clinico-pathological variables were also assessed.
  
  
  RESULTS
  HER2 protein overexpression was detected in 30/44 (68.2%) pT1GIII lesions and predicted recurrence in this subgroup of bladder TCC (p<0.01). Negative HER2 expression was detected in 26/40 (65%) cases with pT1GII TCC, and this condition was more frequent in unifocal tumours, without angiogenesis, with low recurrence rate and without progression. Recurrence-free survival can also be anticipated by HER 2 expression within pT1GII tumours (p<0.01).
  
  
  CONCLUSIONS
  HER2 expression using Hercep test may be useful to predict recurrence in non-muscle invasive bladder TCC. The potential application of this study, especially regarding prediction of response to BCG, should be prospectively confirmed in multi-institutional trials.
authors.affiliation: Departamento de Urología, Hospital Militar Universitario Mohamed V, Rabat, Marruecos. a.janane@yahoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Janane
authors.forename: F
authors.initials: F
authors.lastname: Hajji
authors.forename: T O
authors.initials: TO
authors.lastname: Ismail
authors.forename: J C
authors.initials: JC
authors.lastname: Elondo
authors.forename: M
authors.initials: M
authors.lastname: Ghadouane
authors.forename: A
authors.initials: A
authors.lastname: Ameur
authors.forename: M
authors.initials: M
authors.lastname: Abbar
authors.forename: A
authors.initials: A
authors.lastname: Bouzidi
mesh_terms: D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000098:blood supply / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015653:Cystectomy; D003558:Cystoscopy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D040081:Protein Array Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D016037:Single-Blind Method; D001749:Urinary Bladder Neoplasms / Q000098:blood supply / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery
chemical_list: D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human